



Autism Spectrum Disorder as a Brain-Gut-Microbiome Axis Disorder

Virginia Saurman¹ · Kara G. Margolis¹ · Ruth Ann Luna²

© Springer Science+Business Media, LLC, part of Springer Nature 2020

Abstract

While there are numerous medical comorbidities associated with ASD, gastrointestinal (GI) issues have a significant impact on quality of life for these individuals. Recent findings continue to support the relationship between the gut microbiome and both GI symptoms and behavior, but the heterogeneity within the autism spectrum requires in-depth clinical characterization of these clinical cohorts. Large, diverse, well-controlled studies in this area of research are still needed. Although there is still much to discover about the brain-gut-microbiome axis in ASD, microbially mediated therapies, specifically probiotics and fecal microbiota transplantation have shown promise in the treatment of GI symptoms in ASD, with potential benefit to the core behavioral symptoms of ASD as well. Future research and clinical trials must increasingly consider complex phenotypes in ASD in stratification of large datasets as well as in design of inclusion criteria for individual therapeutic interventions.

Keywords Autism spectrum disorders · Gastrointestinal · Microbiome · Brain-gut axis



Virginia Saurman



Kara G. Margolis



Ruth Ann Luna

Kara G. Margolis and Ruth Ann Luna are co-senior authors.

✉ Ruth Ann Luna
raluna@bcm.edu

Virginia Saurman
svirginie307@gmail.com

Kara G. Margolis
kjg2133@cumc.columbia.edu

¹ Department of Pediatrics, Columbia University Medical Center, 620 West 168th Street, New York, NY 10032, USA

² Department of Pathology and Immunology, Texas Children's Microbiome Center, Baylor College of Medicine, Texas Children's Hospital, Feigin Tower, 1102 Bates Avenue, Suite 955, Houston, TX 77030, USA

Introduction

Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by persistent deficits in social communication and repetitive behavioral patterns. Current statistics suggest that ASD affects 1 in 59 children throughout the USA [1]. Although the diagnosis of ASD is exclusively neurobehavioral, ASD is accompanied by many medical comorbidities that often occur in much higher prevalence than in neurotypical children. Among these co-occurring medical conditions, gastrointestinal (GI) problems are among the most common.

GI disorders are approximately fourfold more prevalent in children with ASD than in the neurotypical population. Although all of the same GI disorders that present in neurotypical individuals can also be found in those with ASD, constipation and diarrhea tend to be the most common [2, 3]. There have been strong correlations found between GI dysfunction and multiple other comorbidities. For example, functional constipation in children with ASD has been associated with worsened behavioral symptoms, as well as an increase in cortisol, stress, and anxiety [4–14]. Other CNS-based comorbidities in the ASD population, such as seizures and sleep disorders, also present more commonly in association with GI dysfunction [3, 15–17].

The high prevalence of GI dysfunction in ASD and its significant correlations with challenging behaviors and psychiatric comorbidities suggest that there is a relationship between gut and brain dysfunction in a significant subset of these individuals. Insight into the mechanisms that cause dysfunction in brain-gut communication may thus lead to a greater understanding of the underlying pathophysiology of the brain-gut axis in patients with ASD and, moreover, lead to the discovery of novel therapeutic targets. There is increasing evidence to suggest that one of the key modulators of gut-brain communication in ASD is the intestinal microbiome.

The brain-gut-microbiome axis has become a compelling area of investigation in ASD, specifically in the pediatric population (Fig. 1). Characterization of the gut microbiome, usually profiled by sequencing the 16S rRNA gene in bacteria isolated from stool, has been increasingly employed in pediatric GI disorders over the past decade. Unique microbial patterns have been identified in a variety of functional GI disorders like irritable bowel syndrome and recurrent abdominal pain as well as in inflammatory disorders such as inflammatory bowel disease [18–23]. Pilot studies with small cohorts have expanded into large multicenter studies that are now beginning to provide the power to identify robust patterns in these GI conditions, and ASD research is just beginning to benefit from these studies. In this review, we will discuss the potential role of




Fig. 1 The brain-gut-microbiome axis plays an important role in autism spectrum disorder. Differences exist in the gut microbiome of typically developing children compared to children with autism spectrum disorder. However, these changes to the microbial community are affected by differences in diet, medication regimens, medical comorbidities, geographic location, and both acute and chronic GI symptoms. In addition, the brain-gut-microbiome axis is bidirectional with regard to changes in both the gut (GI symptoms and microbial profile) and behavior

the gut in ASD with a focus on the current state of knowledge of the gut microbiome in this population.

Gut Microbiome and ASD

The role of the gut microbiome in ASD was first questioned with the emergence of anecdotal reports of young children who developed regressive ASD after repeated exposure to antibiotics for chronic otitis media [24, 25]. The clinical course described in this subset of children included the development of chronic diarrhea post-antibiotic administration that was quickly followed by a loss of language and social skills [26, 27]. The initial hypothesis, which was generated in part by Ellen Bolte [26], a mother of a child who with regressive ASD, implicated anaerobic bacteria, namely Clostridiales, based on their ability to produce neurotoxins [28]. Bolte was also the first individual to report an overall improvement in ASD symptoms when her son was given additional antibiotics targeted to eradication of Clostridiales, leading to further research on the possibility that antibiotics could effect change in the core symptoms of ASD [29].

The notion that Clostridiales could be an underlying factor in ASD-associated symptoms for regressive ASD set the foundation for the first open-label clinical trial of

vancomycin, an antibiotic known to treat Clostridia [30], in kids with regressive ASD. The inclusion criteria for the study created a unique subgroup of ASD, specifically those who developed ASD-like symptoms and diarrhea after antibiotic exposure in early childhood and who continued to have GI issues and significant communication difficulties post-antibiotic exposure. Each subject was given an 8 week course of vancomycin followed by 4 weeks of oral probiotics (*L. acidophilus*, *L. bulgaricus*, and *B. bifidum*) [24]. Interestingly, eight of the 11 individuals who received vancomycin showed substantial behavioral improvements. The majority of subjects, however, experienced substantial behavioral deterioration within 2 weeks after vancomycin cessation [24]. Although there were significant limitations in the study, including small sample size, lack of an untreated control group, and an open-label study design [31, 32], it was a crucial first step in support of the hypothesis that changes in the gut microbiome could elicit changes in the core symptoms of ASD.

A number of studies over the past 20 years have reconfirmed the finding that stool from some individuals with ASD may harbor distinct Clostridial species relative to neurotypical individuals [27, 33–40]. *Clostridium* (*Lachnospirillum*) *bolteae* has specifically been associated with ASD patients with GI problems [34, 36, 41]. Despite these differences in proportions, the ways in which Clostridiales impacts host physiology in ASD are not yet known. Blood samples from some ASD patients demonstrate increased levels of metabolites that are chemically similar to p-cresol (e.g., 4-Ethylphenylsulfate), a neurotoxin produced by Clostridiales [42, 43]. This finding supports the hypothesis that Clostridiales produce neurotoxins. Studies have not been done, however, to confirm a connection between increased levels of 4-Ethylphenylsulfate and deleterious effects on brain or enteric nervous system development or function.

Extensive Diversity of Current Studies: Background and Implications

In addition to Clostridiales, multiple distinct microbiota populations have been demonstrated in individuals with ASD compared to neurotypical controls, and these studies have been done almost exclusively in children [27, 33–36, 39–41, 44]. It is important to note that these studies have generated highly divergent results [45]. Underlying reasons for this discordance in findings include recruitment of small cohorts, utilization of unaffected siblings as the singular control group, and failure to control for key modulators of the microbiome, including diet, antibiotic exposure, probiotic intake, and both over-the-counter and prescription medications (Fig. 1) [46–48]. Individuals with ASD often have highly self-restrictive diets, which have been shown to affect gut microbiota [49]. GI motility issues,

including constipation and diarrhea, have also been shown to affect the microbiome (and vice versa) and, as stated above, are also common in individuals with ASD [2, 3, 12, 50, 51]. Finally, it is exceedingly difficult to account for the extensive genetic and medical heterogeneity inherent in the ASD population which may also impact microbial composition [2, 3, 52].

Beyond variation in study design and population, laboratory and analytic techniques employed in the study of the microbiome have differed vastly as technology has rapidly advanced. As the cost of sequencing has decreased, studies have exponentially increased average sequencing depth. This continuous advancement, paired with more complete microbially focused databases, has increased the level of resolution in the microbiome field yet has also contributed to the diversity of outcomes based on the type of technology utilized. For example, the earlier studies, that detected an increased abundance of *Clostridium* species in the GI tracts of ASD patients [27, 36, 39], utilized stool-based culture and RT-PCR. The results of this research was much more limited in that stool bacteria was examined at higher taxonomic levels rather than at the species or OTU level [33, 34, 38, 41]. The next phase of studies, that incorporated next-generation sequencing, were more specific but continued to exhibit clinical study limitations, as detailed above. As the studies in the USA evolved from PCR-based or culture-enhanced characterization of the microbiome, the findings of previous studies in pediatric ASD failed to be replicated [33, 38] with some studies unable to identify any statistically significant differences in microbiota between the ASD and control groups [37, 40].

Geographic location is known to affect microbiome profiles, and diet is thought to be the major driver behind those differences. While the initial studies that sought to evaluate the microbiota in ASD were mainly conducted in the USA, recent publications are now offering a glimpse into how gut microbiome profiles in ASD differ across several countries including Italy [53, 54], India [55], Spain [56], China [57], and Ecuador [58]. As expected, even though these individual studies highlight differences between the ASD and control groups, there is very little consistency of findings across these studies. For example, two recent studies both conducted in Italy failed to reach consensus at even the phylum level, with one study reporting a decrease in Bacteroidetes [54] while the other reported an increase [53]. It is worth noting that, in contrast to the former study, the latter focused on young children (ages 2–4 years) and age stratification is a crucial point of analysis in the evaluation of the developing gut microbiome in pediatric ASD. Studies with larger cohorts, including multi-site recruitment from diverse geographic locations, that are integrating a critical mass of data related to the clinical phenotype (Fig. 1), with GI and behavioral

components, as well as addressing dietary differences, are thus greatly needed in this population.

Stool Versus Tissue Microbiota: Is There a Difference?

Most current studies have evaluated the intestinal microbiome in ASD patients through stool. Though stool collection is a less invasive option, evaluation of microbiota that lay directly on the intestinal mucosa may be more highly indicative of the direct interactions that specific microbiota have with the gut mucosa, as well as their impact on host physiology [59–64]. There have been two studies published thus far that have sought to identify a mucosal microbiome in ASD [44, 65]. The initial study utilized next-generation sequencing to evaluate ileal and cecal mucosal biopsy specimens from children with and without ASD. There were differences in the microbiota composition between the children with ASD and neurotypical children, including increases in Clostridiales, specifically *Lachnospiraceae* and *Ruminococcaceae* [44]. The investigators further found that these microbiota shifts were associated with lower mRNA levels of genes important for carbohydrate digestion (e.g., disaccharidases and hexose transporters). This was an interesting finding because there have been multiple anecdotal reports describing behavioral and GI improvements in children with ASD placed on gluten-free/low carbohydrate diets [66]. Lack of adequate carbohydrate breakdown and absorption has been shown to lead to fermentation, gas production and increased gut osmotic load which results in bloating, abdominal pain and diarrhea with carbohydrate intake [44]. Although the double-blind, placebo-controlled studies have not shown differences in behavior or GI symptoms after a gluten-free diet, this study was important in that it was the first to provide a potential explanation for why some children with ASD may respond well to gluten free and/or low carbohydrate diets. The current study, however, was small and included patients with a diverse array of GI motility problems (e.g., constipation versus diarrhea). If these findings were to be reconfirmed in a larger population of children whose clinical metadata is more clearly defined, this could be an important insight into how diet can be used as therapy for a subset of individuals with ASD. It is also important that the precise functional roles of the bacteria associated with these changes in hexose transporters and disaccharidases be investigated.

A more recent study that focused on the relationship between the mucosal microbiome in children with and without ASD specifically was advantageous in that included children with ASD who also met the criteria for a functional GI disorder (FGID) [2, 67], the most common type of GI problems

affecting this population. The ASD and neurotypical (NT) children evaluated were grouped based on their FGID status as assessed by the Questionnaire on Pediatric Gastrointestinal Symptoms-Rome III (QPGS-RIII) and endoscopic findings (ASD-FGID, NT-FGID, NT). The investigators found novel correlations from not only those patients with ASD compared to neurotypical children, but also those individuals with ASD and abdominal pain compared to those without pain. As seen in prior stool-derived microbiota studies, there was a significant increase in several Clostridiales species, but here it was noted specifically in the population of children with ASD who also had a diagnosis of FGID, indicating a novel association between Clostridiales, ASD, and FGIDs [65]. Several of the *Clostridium sp.* were also found to correlate significantly with proinflammatory cytokines (IL-6, IL-1, IL-17, and INF-gamma) as well as tryptophan and serotonin, indicative of newly identified potential links between the intestinal microbiota, serotonin and/or tryptophan secretion as well as inflammation [65]. These correlations thus yielded the first multi-omic profile specific to ASD-FGID and ASD-FGID with abdominal pain and identified novel human-relevant associations between specific microbiota, gut neurotransmitters and immunity. Finally, the data also may provide some insight into how serotonin affects gut function in these individuals. Almost a third of individuals with ASD have high blood serotonin levels [68]. Children with ASD and hyperserotonemia have also been found to exhibit higher levels of lower GI tract problems (e.g., constipation) [4]. This may be linked to bidirectional communication with the gut microbiota; gut bacteria can synthesize serotonin, increases in host serotonin levels can impact gut microbiota composition and, further, specific bacteria (i.e., *Turicibacter sanguinis*) may actually possess a serotonin “sensor” that takes up serotonin with consequent effects on its colonization and host physiology [61, 62, 69]. These correlates have been demonstrated in several transgenic murine models, including the BTBR T+Itpr3tf/J (Black and Tan BRachyury with inserted *tufted* inositol 1,4,5-triphosphate receptor 3 delta as a marker) and the SERT Ala56 (serotonin reuptake transporter alanine 56 substitution) mice, that exhibit core behavioral phenotypes of ASD, as well as alterations in intestinal microbiota that correlate with delayed GI transit and impaired serotonin signaling [70, 71] (and pilot data by Luna and Margolis).

Altogether, these data suggest that alteration of the microbiota is associated with changes in the gut-neuro-immune axis. They also provide the basis for much larger studies, both clinical and functional, to identify the roles of specific microbiota in behavioral and gut dysfunction in ASD and also the utility of serotonin-based modulators as potential therapeutic targets.

Genetic Abnormalities and Environmental Exposures Contribute to ASD Risk: Understanding the Underlying Mechanisms in Relation to the Gut Microbiome

Although there have been many studies that demonstrate that the microbiota community in individuals with ASD is different, the specific microbiota involved and their functional effects on ASD development and/or the perpetuation of ASD-associated behaviors remain largely unknown. Although still in its infancy, the examination of this field in murine studies has begun to elucidate potentially important links between environmental risk factors, the microbiota and ASD development.

A number of murine studies support the notion that genetic abnormalities and/or environmental exposures that affect brain development and function also impact gut function [72–77]. The microbiome has been increasingly shown to play a role in these gene-environmental interactions. Gnotobiotic mice and/or rats, for example, that are born and raised in the absence of microbial colonization, exhibit aberrations in several complex behaviors diagnostic of ASD including decreased sociability, repetitive stereotyped behaviors and impaired social behaviors, when introduced to new partners [78]. Some of these deficits, further, can be reversed by the administration of probiotics or co-housing with WT mice [79–84]. Underlying these observations are evidence that intestinal microbiota impact brain development in areas critical for emotion and mood. Gnotobiotic mice, for example, exhibit gene expression changes in the amygdala, a key region for emotional responses [85]. They also have increased hippocampal serotonergic neurons, in male mice, and decreased hippocampal brain-derived neurotrophic factor levels [80, 86]. The dorsal hippocampus plays a role in spatial learning and memory, while the ventral hippocampus preferentially regulates anxiety and the stress response. These abnormalities in CNS development correlate with behavioral disturbances in ASD, including stereotypies and decreased socialization [80].

In addition to its impact on the brain and behavior, the microbiome may also impact the gut itself. Gnotobiotic mice also exhibit gut abnormalities, including increased gut permeability and slowed motility [79, 87–91]. Gut dysfunction may be causative of CNS disturbance; it has been shown in prior mouse studies that increased intestinal permeability allows for the passage of proinflammatory mediators and/or hormones into the circulation, where they may be transported through the bloodstream to the brain, where they may ultimately impact CNS neurodevelopment and/or function [62–64, 69, 75, 92, 93]. Consequently, any genetic predisposition or maternal exposure that impacts

the intestinal microbiome could have implications on both brain and intestinal function.

Two exposures that have been linked to ASD development in clinical epidemiological studies are maternal obesity and maternal inflammation [60]. Mouse models of maternal obesity and maternal infection are also linked with development of ASD in progeny and, further, have implicated the microbiome in their underlying pathology.

In the USA, ~one-third of women are obese [94, 95] and there has been a coincident rise in both obesity and neuropsychiatric disorders [96]. A mouse model of maternal obesity, induced by a maternal high-fat diet (MHFD), has been shown to result in ASD-like behaviors as well as changes in the CNS in resulting progeny. MHFD-exposed pups exhibit reduced vocalizations and disruptions in exploratory, cognitive, and stereotyped behaviors [72, 73, 82]. They also have fewer oxytocinergic neurons in the hypothalamus and impaired mesolimbic (dopaminergic) system function. Interestingly, these pups exhibit a dysbiosis characterized, in part, by lower levels of *Lactobacillus reuteri*, compared to controls [72, 82]. When *Lactobacillus reuteri* is replenished or oxytocin is administered, however, there is a reversal of the abnormal brain and behavioral findings, implicating a potential role for the microbiome in brain oxytocin production [82]. It was further shown by these investigators that the vagal nerve stimulation that induces oxytocin release, by projecting fibers into the paraventricular nuclei (PVN) which synthesize oxytocin in the brain, is triggered by *L. reuteri*, a hypothesis further confirmed by the lack of oxytocin release after vagotomy. A later study by the same laboratory determined that *L. reuteri* supplementation also increased the number and intensity of fluorescence of oxytocinergic neurons in the PVN in Shank3BKO mice, another mouse model of ASD with a genetic mutation found in Phelan McDermid syndrome. These findings together suggest that the microbiome may alter brain activity and behavior by stimulating the vagus nerve to increase PVN production of oxytocin. These findings have a clinical correlate in that there are anecdotal reports of behavioral improvements after oxytocin administration [97, 98].

L. reuteri is unlikely, however, to be the only microbe affected by high-fat diet exposure. A complementary study was done in which pregnant female mice were subjected to a microbiome depletion/transplantation paradigm. Antibiotics were used for microbial clearance and were followed by transplantation with microbiota isolated from donors on a high-fat diet, throughout pregnancy and breastfeeding. Male and female high-fat diet fed pups both had significantly decreased communication compared to controls while males exhibited significantly decreased amounts of exploratory time, an increase in stereotyped behaviors and impaired learning. Metagenomic R16S analysis suggested that decreased representation of particular species of the

Firmicutes phylum was predictive of behavioral declines in male HFD pups [72].

The link between maternal infection and ASD originates from a large epidemiological study that showed strong associations between peripartum infections, specifically first trimester viral infections or second trimester bacterial infections, and ASD risk [99]. A subsequent prospective cohort analysis of over 100,000 women showed that maternal influenza infection or episodes of fevers lasting more than 7 days during pregnancy are associated with a two- and three-fold increased risk of ASD, respectively [100].

A highly validated mouse model of maternal inflammation is the maternal immune activation (MIA) model, in which mouse dams are injected with the viral mimetic, poly(I:C). Studies of this model have revealed connections between maternal inflammation, enteric microbiome changes and abnormalities in brain-gut development and function [75, 76, 84, 101, 102]. Resulting offspring of maternal dams exposed to poly(I:C) exhibit deficits in core communication and social behaviors as well as stereotypical movements reminiscent of ASD [75]. In addition to the neurobehavioral deficits, these mice exhibit increased gut permeability accompanied by decreased expression of gastrointestinal tight junction proteins, and microbial dysbiosis characterized by changes in the populations of Clostridia, Bacterioides and Lachnospiraceae. These differences were associated with several abnormalities in serum metabolites, including increased levels of indolpyruvate, 5-HT, and 4-ethylphenylsulfate (4-EPS). Interestingly, oral gavage of *B. fragilis* corrected the dysbiosis, corrected the serum abnormalities in indolpyruvate and 4-EPS, and resulted in improvement of the behavioral abnormalities [84]. Because the gut permeability was also normalized after *B. fragilis* exposure, the investigators suggested that this microbial supplement repaired the intestinal barrier, thereby preventing leakage of toxic molecules (e.g., 4-EPS) into the serum which could not then circulate to the brain.

The proinflammatory cytokine, IL-6 has been implicated in the pathogenesis underlying the MIA models [75, 103]. In addition to its proinflammatory effects, IL-6 exhibits a robust inverse relationship with full scale intelligence quotient (FSIQ) scores and socialization scores in ASD patients, indicating a potential relationship between inflammation and behavior [5]. Interestingly, increases in IL-6 have also been linked to changes in intestinal tight junction expression and intestinal barrier integrity suggesting that the cytokine could be a link between inflammation, tight junction integrity and behavioral dysfunction [104]. Given the apparent microbial modulation of gut and brain function in MIA models and the repeated observation that IL-6 and the microbiome impact each others' regulation, it is possible that the underlying connection between IL-6, inflammation, and gut-brain dysfunction lies in its ability to modulate the microbiome, or vice

versa [105–107]. Conversely, however, enteric microbes are also known to regulate intestinal tight junction and cytokine levels, suggestive of the idea that the microbiome may be a cause of the inflammation associated with maternal infection [108].

Other environmental exposure or genetic mouse models that exhibit impaired social behaviors and microbial dysbiosis, for which there is less data available, include a valproic acid exposure model and the BTBR T+ Itpr3tf/J mice [70, 109]. Interestingly, social deficits observed in the BTBR T+ Itpr3tf/J mice can be reversed by co-housing with their WT counterparts, making the microbiota a possible modulator for ASD-associated behavior in these mice as well [110].

In contrast to maternal infection/maternal immune activation and maternal obesity, an environmental exposure that may be protective against ASD is the ketogenic diet (KD). The KD has been used to manage epilepsy for nearly a century [111], including the treatment of epilepsy syndromes where ASD is a core symptom [112, 113]. Interestingly, however, the KD has also been shown to relieve ASD-associated behaviors in some of these patients. There are several case reports of Rett syndrome patients who exhibited improvements in sociability and contact behavior after being placed on a KD [114]. These findings have been replicated in several mouse models; the KD has been shown to improve sociability in environmental exposure mouse models, including those subjected to MIA or valproic acid during development [77, 111, 115] and also in three genetically modified mouse models of ASD, the BTBR model [116], the EL strain (a strain used in epilepsy research) [117], and the genetic variant *Engrailed 2* gene [118].

The mechanism linking the KD to seizure amelioration and sociability improvement remains unclear [111] though it has been suggested that these changes may result from microbial differences that emerge from the dietary changes. KD alters the composition of gut microbiota in mice [119, 120], as well as in humans [121, 122] BTBR mice have been shown to have fecal microbiota composition similar to that of some individuals with ASD, including elevated levels of Clostridiales cluster XI [39], decreased Firmicutes and increased Bacteroidetes sp [33, 34] as well as increased levels of *Akkermansia muciniphila* [33, 34, 120]. The fecal and cecal low Firmicutes: Bacteroidetes ratio in BTBR mice, as well as the elevated levels of *Akkermansia muciniphila*, is both reversed by the KD [120]. The studies evaluating the effects of the KD on the gut microbiota, however, have not been entirely consistent; a KD has also been shown to result in an increase in *Akkermansia* and *Parabacteroides* species in a different study, and, moreover, confers the protective effects of KD against electrically induced seizures in the 6 Hz seizure-induced model [81].

It has been suggested that the link between ASD, the microbiota and seizure activity may all evolve from an

underlying mitochondrial disturbance. Mitochondrial instability is found in many neurodevelopmental disorders, including ASD [123]; moreover, abnormalities in adenosine levels in ASD patients have been observed [124]. Improved mitochondrial function is thought to be a mechanism by which KD functions [125]. In accordance with this postulate, KD has been shown to increase adenosine levels in the CNS, purinergic therapies have been described as improving core symptoms of ASD [126, 127] and KD restored mitochondrial function in the valproic acid exposure model of autism [77]. It has been shown that gut microbiota signal to the mitochondria of mucosal cells, including epithelial cells and immune cells and, further, that this signaling alters mitochondrial metabolism [128]. If this happens in ASD models, however, has not yet been explored.

Potential of Microbially Mediated Therapies in ASD

With mounting evidence for a role of the brain-gut-microbiome axis in ASD, microbially mediated therapies hold significant potential for improving the quality of life for these individuals. We are at the cusp of better understanding the effect of diet on human health and behavior; however, dietary factors are significant modulators of the gut microbiome and thus dietary interventions may be considered a microbially mediated therapy for subsets of individuals with ASD. Gluten- and casein-free (GFCF) diets are commonly utilized in the ASD population even though small yet properly controlled studies fail to show significant improvement [129, 130]. Studies in other parts of the world, however, have shown potential benefit of a GF diet on GI symptoms and behavior in ASD [131] as well as global improvements while on a ketogenic diet [132]. The most recent study took a more comprehensive approach in randomizing children and adults with ASD to a gluten-, casein-, and soy-free (GFCFSF) diet along with a variety of supplements, and after 1 year, the treatment group showed significant improvement in the core symptoms of ASD and developmental age compared to the control group [133]. Larger, well-controlled studies that take into account the clinical heterogeneity in ASD may help to target which individuals may benefit from diets like these.

Clinical trials that evaluate the use of probiotics for the treatment of a variety of GI disorders are ongoing, with many already showing highly favorable results [134]. While probiotics containing a single beneficial bacterial strain have been successful in IBS, formulations containing multiple strains across more than one genera may be more effective in the ASD population; recent trials in ASD using a multi-strain probiotic [135] and a combination of a single strain (*B. infantis*) and colostrum [136] have provided evidence of positive benefits and support the need for larger studies.

Although the initial vancomycin trial in pediatric ASD provided compelling evidence for the potential of antibiotics for treatment of the core symptoms of ASD [24], very little progress has been made on this front. More recently, minocycline as an adjuvant to risperidone was shown to decrease irritability and hyperactivity/noncompliance, but further work is needed to determine if these improvements are sustained [137]. Conversely, a pilot study evaluating the effect of D-cycloserine on core social deficits in ASD showed no improvement in the drug treatment group but improvement in the entire cohort that was attributed to the social skills therapy program [138].

The potential for microbially mediated therapy in general may be best assessed by fecal microbiota transplantation (FMT). Vancomycin is commonly prescribed prior to FMT, as was the case in the only study to investigate the potential efficacy of FMT in children with ASD. An open-label trial of 18 children with ASD included 2 weeks of vancomycin followed by 8 weeks of FMT [139]. Improvement in GI symptoms were seen during FMT treatment and persisted at 8 weeks following treatment cessation. Improvements were also seen in behavioral symptoms of ASD, and increases in *Bifidobacterium*, *Prevotella*, and *Desulfovibrio* in the gut microbiome were seen in parallel. Two years following treatment, improvements in GI symptoms remain as well as improvement in behavioral symptoms and sustained abundances of *Bifidobacterium* and *Prevotella* [140].

An expanded study that includes not only a placebo group but also a vancomycin only group is needed to accurately assess the impact of FMT plus vancomycin versus vancomycin alone. It is also important to consider that individuals with ASD continue to develop albeit at a delayed pace in most cases, so the inclusion of a control group for comparison with regard to GI and behavior will be needed to evaluate long-term outcomes. It will also be important to characterize the gut microbiome in parallel with these positive changes to potentially identify microbial profiles of individuals who were responders to FMT as well as determine the functional microbiome changes that are associated with alleviation of symptoms.

Future of Brain-Gut-Microbiome Axis Research in ASD

There has been a rapid advancement in the knowledge base of the gut microbiome and the technologies used to study it. Despite this vast increase in information, the many factors that confound the current gut microbiome studies in ASD make them impossible to interpret as a whole. With the increased understanding that many factors that impact the microbiome are present in ASD, such medication exposure and GI comorbidities, the inclusion criteria that relies solely

on a “diagnosis of ASD” is no longer acceptable. Future studies must thus incorporate the clinical characteristics that comprise complex phenotypes in ASD. These studies will likely result in the stratification of multiple cohorts rather than “one ASD.” Along these lines, it is likely that interventions that have anecdotally shown promise in individuals with ASD but have failed to show statistically significant improvement in clinical trials may have favorable outcomes when targeted “ideal groups” are identified. Significant effort is also needed in the investigation of the brain-gut-microbiome axis in adults with ASD, as almost all research in this area has been focused on the pediatric population. In conjunction with clinical studies, basic or translational studies are also critically needed to determine the effects of specific microbiota and their impact on host physiology in health and disease. Given all of the data supporting a role for microbial modulation of CNS development, behavior and cognition, it seems a worthwhile goal to pursue these aims as a way of developing novel microbially mediated treatments for this exceptionally hard to treat set of disorders.

Key Points

- There is significant heterogeneity within autism spectrum disorder, including varying levels of severity with regard to behavior, cognitive ability, and medical comorbidities.
- Gastrointestinal symptoms can be difficult to recognize in individuals with ASD with limited communication abilities.
- Preclinical models of ASD have illustrated significant crosstalk along the brain-gut-microbiome axis.
- Complex phenotypes based on in-depth clinical characterization are vital to conducting robust research and clinical trials.
- Microbially mediated therapies are worth further exploration in specific complex phenotypes of ASD.

References

1. Baio J, Wiggins L, Christensen DL, et al. Prevalence of autism spectrum disorder among children aged 8 years—autism and developmental disabilities monitoring network, 11 sites, United States, 2014. *MMWR Surveill Summ*. 2018;67:1–23.
2. McElhanon BO, McCracken C, Karpen S, et al. Gastrointestinal symptoms in autism spectrum disorder: a meta-analysis. *Pediatrics*. 2014;133:872–883.
3. Doshi-Velez F, Ge Y, Kohane I. Comorbidity clusters in autism spectrum disorders: an electronic health record time-series analysis. *Pediatrics*. 2014;133:e54–e63.
4. Marler S, Ferguson BJ, Lee EB, et al. Association of rigid-compulsive behavior with functional constipation in autism spectrum disorder. *J Autism Dev Disord*. 2017;47:1673–1681.
5. Bradley CC, Boan AD, Cohen AP, et al. Reported history of developmental regression and restricted, repetitive behaviors in children with autism spectrum disorders. *J Dev Behav Pediatr*. 2016;37:451–456.
6. Maenner MJ, Arneson CL, Levy SE, et al. Brief report: association between behavioral features and gastrointestinal problems among children with autism spectrum disorder. *J Autism Dev Disord*. 2012;42:1520–1525.
7. Horvath K, Perman JA. Autism and gastrointestinal symptoms. *Curr Gastroenterol Rep*. 2002;4:251–258.
8. Nikolov RN, Bearss KE, Lettinga J, et al. Gastrointestinal symptoms in a sample of children with pervasive developmental disorders. *J Autism Dev Disord*. 2009;39:405–413.
9. Mazurek MO, Vasa RA, Kalb LG, et al. Anxiety, sensory over-responsivity, and gastrointestinal problems in children with autism spectrum disorders. *J Abnorm Child Psychol*. 2013;41:165–176.
10. Gorrindo P, Williams KC, Lee EB, et al. Gastrointestinal dysfunction in autism: parental report, clinical evaluation, and associated factors. *Autism Res*. 2012;5:101–108.
11. Fulceri F, Morelli M, Santocchi E, et al. Gastrointestinal symptoms and behavioral problems in preschoolers with autism spectrum disorder. *Dig Liver Dis*. 2016;48:248–254.
12. Chaidez V, Hansen RL, Hertz-Picciotto I. Gastrointestinal problems in children with autism, developmental delays or typical development. *J Autism Dev Disord*. 2014;44:1117–1127.
13. Mazefsky CA, Schreiber DR, Olino TM, et al. The association between emotional and behavioral problems and gastrointestinal symptoms among children with high-functioning autism. *Autism*. 2014;18:493–501.
14. Ferguson BJ, Dovgan K, Takahashi N, et al. The relationship among gastrointestinal symptoms, problem behaviors, and internalizing symptoms in children and adolescents with autism spectrum disorder. *Front Psychiatry*. 2019;10:194.
15. Mouridsen SE, Rich B, Isager T. Epilepsy in disintegrative psychosis and infantile autism: a long-term validation study. *Dev Med Child Neurol*. 1999;41:110–114.
16. Tuchman R, Rapin I. Epilepsy in autism. *Lancet Neurol*. 2002;1:352–358.
17. Richdale AL, Schreck KA. Sleep problems in autism spectrum disorders: prevalence, nature, and possible biopsychosocial aetiologies. *Sleep Med Rev*. 2009;13:403–411.
18. Hollister EB, Oezguen N, Chumpitazi BP, et al. Leveraging human microbiome features to diagnose and stratify children with irritable bowel syndrome. *J Mol Diagn*. 2019;21:449–461.
19. Vich Vila A, Imhann F, Collij V, et al. Gut microbiota composition and functional changes in inflammatory bowel disease and irritable bowel syndrome. *Sci Transl Med*. 2018;10:eaap8914.
20. Shankar V, Reo NV, Paliy O. Simultaneous fecal microbial and metabolite profiling enables accurate classification of pediatric irritable bowel syndrome. *Microbiome*. 2015;3:73.
21. Nafarin AR, Hegar B, Sjakti HA, et al. Gut microbiome pattern in adolescents with functional gastrointestinal disease. *Int J Pediatr Adolesc Med*. 2019;6:12–15.
22. Saulnier DM, Riehle K, Mistretta TA, et al. Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome. *Gastroenterology*. 2011;141:1782–1791.
23. Lo Presti A, Zorzi F, Del Chierico F, et al. Fecal and mucosal microbiota profiling in irritable bowel syndrome and inflammatory bowel disease. *Front Microbiol*. 2019;10:1655.
24. Sandler RH, Finegold SM, Bolte ER, et al. Short-term benefit from oral vancomycin treatment of regressive-onset autism. *J Child Neurol*. 2000;15:429–435.
25. Wimberley T, Agerbo E, Pedersen CB, et al. Otitis media, antibiotics, and risk of autism spectrum disorder. *Autism Res*. 2018;11:1432–1440.

26. Bolte ER. Autism and Clostridium tetani. *Med Hypotheses*. 1998;51:133–144.
27. Finegold SM, Molitoris D, Song Y, et al. Gastrointestinal microflora studies in late-onset autism. *Clin Infect Dis*. 2002;35:S6–S16.
28. Montecucco C, Schiavo G. Mechanism of action of tetanus and botulinum neurotoxins. *Mol Microbiol*. 1994;13:1–8.
29. Rodakis J. An $n = 1$ case report of a child with autism improving on antibiotics and a father's quest to understand what it may mean. *Microb Ecol Health Dis*. 2015;26:26382.
30. Van Bambeke F, Van Laethem Y, Courvalin P, et al. Glycopeptide antibiotics. *Drugs*. 2004;64:913–936.
31. Sandler AD, Sutton KA, DeWeese J, et al. Lack of benefit of a single dose of synthetic human secretin in the treatment of autism and pervasive developmental disorder. *N Engl J Med*. 1999;341:1801–1806.
32. Lasagna L, Mosteller F, Von Felsinger JM, et al. A study of the placebo response. *Am J Med*. 1954;16:770–779.
33. De Angelis M, Piccolo M, Vannini L, et al. Fecal microbiota and metabolome of children with autism and pervasive developmental disorder not otherwise specified. *PLoS ONE*. 2013;8:e76993.
34. Finegold SM, Dowd SE, Gontcharova V, et al. Pyrosequencing study of fecal microflora of autistic and control children. *Anaerobe*. 2010;16:444–453.
35. Finegold SM, Summanen PH, Downes J, et al. Detection of Clostridium perfringens toxin genes in the gut microbiota of autistic children. *Anaerobe*. 2017;45:133–137.
36. Song Y, Liu C, Finegold SM. Real-time PCR quantitation of clostridia in feces of autistic children. *Appl Environ Microbiol*. 2004;70:6459–6465.
37. Gondalia SV, Palombo EA, Knowles SR, et al. Molecular characterisation of gastrointestinal microbiota of children with autism (with and without gastrointestinal dysfunction) and their neurotypical siblings. *Autism Res*. 2012;5:419–427.
38. Kang DW, Park JG, Ilhan ZE, et al. Reduced incidence of Prevotella and other fermenters in intestinal microflora of autistic children. *PLoS ONE*. 2013;8:e68322.
39. Parracho HM, Bingham MO, Gibson GR, et al. Differences between the gut microflora of children with autistic spectrum disorders and that of healthy children. *J Med Microbiol*. 2005;54:987–991.
40. Son JS, Zheng LJ, Rowehl LM, et al. Comparison of fecal microbiota in children with autism spectrum disorders and neurotypical siblings in the simons simplex collection. *PLoS ONE*. 2015;10:e0137725.
41. Wang L, Christophersen CT, Soric MJ, et al. Increased abundance of Sutterella spp. and Ruminococcus torques in feces of children with autism spectrum disorder. *Mol Autism*. 2013;4:42.
42. Altieri L, Neri C, Sacco R, et al. Urinary p-cresol is elevated in small children with severe autism spectrum disorder. *Biomarkers*. 2011;16:252–260.
43. Persico AM, Napolioni V. Urinary p-cresol in autism spectrum disorder. *Neurotoxicol Teratol*. 2013;36:82–90.
44. Williams BL, Hornig M, Buie T, et al. Impaired carbohydrate digestion and transport and mucosal dysbiosis in the intestines of children with autism and gastrointestinal disturbances. *PLoS ONE*. 2011;6:e24585.
45. Ding HT, Taur Y, Walkup JT. Gut microbiota and autism: key concepts and findings. *J Autism Dev Disord*. 2017;47:480–489.
46. Backhed F, Roswall J, Peng Y, et al. Dynamics and stabilization of the human gut microbiome during the first year of life. *Cell Host Microbe*. 2015;17:690–703.
47. Koenig JE, Spor A, Scalfone N, et al. Succession of microbial consortia in the developing infant gut microbiome. *Proc Natl Acad Sci USA*. 2011;108:4578–4585.
48. Yassour M, Vatanen T, Siljander H, et al. Natural history of the infant gut microbiome and impact of antibiotic treatment on bacterial strain diversity and stability. *Sci Transl Med*. 2016;8:343ra81.
49. Berding K, Donovan SM. Diet can impact microbiota composition in children with autism spectrum disorder. *Front Neurosci*. 2018;12:515.
50. Anitha M, Vijay-Kumar M, Sitaraman SV, et al. Gut microbial products regulate murine gastrointestinal motility via Toll-like receptor 4 signaling. *Gastroenterology*. 2012;143:e4.
51. Buie T, Campbell DB, Fuchs GJ 3rd, et al. Evaluation, diagnosis, and treatment of gastrointestinal disorders in individuals with ASDs: a consensus report. *Pediatrics*. 2010;125:S1–S18.
52. Christensen DL, Maenner MJ, Bilder D, et al. Prevalence and characteristics of autism spectrum disorder among children aged 4 years—early autism and developmental disabilities monitoring network, seven sites, United States, 2010, 2012, and 2014. *MMWR Surveill Summ*. 2019;68:1–19.
53. Coretti L, Paparo L, Riccio MP, et al. Gut microbiota features in young children with autism spectrum disorders. *Front Microbiol*. 2018;9:3146.
54. Strati F, Cavalieri D, Albanese D, et al. New evidences on the altered gut microbiota in autism spectrum disorders. *Microbiome*. 2017;5:24.
55. Pulikkan J, Maji A, Dhakan DB, et al. Gut microbial dysbiosis in indian children with autism spectrum disorders. *Microb Ecol*. 2018;76:1102–1114.
56. Plaza-Diaz J, Gomez-Fernandez A, Chueca N, et al. Autism spectrum disorder (ASD) with and without mental regression is associated with changes in the fecal microbiota. *Nutrients*. 2019;11:337.
57. Ma B, Liang J, Dai M, et al. Altered gut microbiota in chinese children with autism spectrum disorders. *Front Cell Infect Microbiol*. 2019;9:40.
58. Zurita MF, Cardenas PA, Sandoval ME, et al. Analysis of gut microbiome, nutrition and immune status in autism spectrum disorder: a case-control study in Ecuador. *Gut Microbes*. 2019. <https://doi.org/10.1080/19490976.2019.1662260>.
59. Wang W, Chen L, Zhou R, et al. Increased proportions of Bifidobacterium and the Lactobacillus group and loss of butyrate-producing bacteria in inflammatory bowel disease. *J Clin Microbiol*. 2014;52:398–406.
60. Li G, Yang M, Zhou K, et al. Diversity of duodenal and rectal microbiota in biopsy tissues and luminal contents in healthy volunteers. *J Microbiol Biotechnol*. 2015;25:1136–1145.
61. Reigstad CS, Salmonson CE, Rainey JF 3rd, et al. Gut microbes promote colonic serotonin production through an effect of short-chain fatty acids on enterochromaffin cells. *FASEB J*. 2015;29:1395–1403.
62. Yano JM, Yu K, Donaldson GP, et al. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. *Cell*. 2015;161:264–276.
63. Atarashi K, Tanoue T, Ando M, et al. Th17 cell induction by adhesion of microbes to intestinal epithelial cells. *Cell*. 2015;163:367–380.
64. Ohnmacht C, Park JH, Cording S, et al. Mucosal immunology. The microbiota regulates type 2 immunity through RORgammat(+) T cells. *Science*. 2015;349:989–993.
65. Luna RA, Oezguen N, Balderas M, et al. Distinct microbiome-neuroimmune signatures correlate with functional abdominal pain in children with autism spectrum disorder. *Cell Mol Gastroenterol Hepatol*. 2017;3:218–230.
66. Knivsberg AM, Reichelt KL, Høien T, et al. A randomised, controlled study of dietary intervention in autistic syndromes. *Nutr Neurosci*. 2002;5:251–261.

67. Margolis KG, Buie TM, Turner JB, et al. Development of a brief parent-report screen for common gastrointestinal disorders in autism spectrum disorder. *J Autism Dev Disord*. 2019;49:349–362.
68. Marler S, Ferguson BJ, Lee EB, et al. Brief report: whole blood serotonin levels and gastrointestinal symptoms in autism spectrum disorder. *J Autism Dev Disord*. 2016;46:1124–1130.
69. Fung TC, Vuong HE, Luna CDG, et al. Intestinal serotonin and fluoxetine exposure modulate bacterial colonization in the gut. *Nat Microbiol*. 2019;4:2064–2073.
70. Golubeva AV, Joyce SA, Moloney G, et al. Microbiota-related changes in bile acid and tryptophan metabolism are associated with gastrointestinal dysfunction in a mouse model of autism. *EBioMedicine*. 2017;24:166–178.
71. Margolis KG, Li Z, Stevanovic K, et al. Serotonin transporter variant drives preventable gastrointestinal abnormalities in development and function. *J Clin Invest*. 2016;126:2221–2235.
72. Bruce-Keller AJ, Fernandez-Kim SO, Townsend RL, et al. Maternal obese-type gut microbiota differentially impact cognition, anxiety and compulsive behavior in male and female offspring in mice. *PLoS ONE*. 2017;12:e0175577.
73. Sgritta M, Dooling SW, Buffington SA, et al. Mechanisms underlying microbial-mediated changes in social behavior in mouse models of autism spectrum disorder. *Neuron*. 2019;101:e6.
74. Jiang YH, Ehlers MD. Modeling autism by SHANK gene mutations in mice. *Neuron*. 2013;78:8–27.
75. Hsiao EY, McBride SW, Chow J, et al. Modeling an autism risk factor in mice leads to permanent immune dysregulation. *Proc Natl Acad Sci USA*. 2012;109:12776–12781.
76. Choi GB, Yim YS, Wong H, et al. The maternal interleukin-17a pathway in mice promotes autism-like phenotypes in offspring. *Science*. 2016;351:933–939.
77. Ahn Y, Narous M, Tobias R, et al. The ketogenic diet modifies social and metabolic alterations identified in the prenatal valproic acid model of autism spectrum disorder. *Dev Neurosci*. 2014;36:371–380.
78. Crumeyrolle-Arias M, Jaglin M, Bruneau A, et al. Absence of the gut microbiota enhances anxiety-like behavior and neuroendocrine response to acute stress in rats. *Psychoneuroendocrinology*. 2014;42:207–217.
79. Sharon G, Sampson TR, Geschwind DH, et al. The central nervous system and the gut microbiome. *Cell*. 2016;167:915–932.
80. Desbonnet L, Clarke G, Shanahan F, et al. Microbiota is essential for social development in the mouse. *Mol Psychiatry*. 2014;19:146–148.
81. Olson CA, Vuong HE, Yano JM, et al. The gut microbiota mediates the anti-seizure effects of the ketogenic diet. *Cell*. 2018;174:497.
82. Buffington SA, Di Prisco GV, Auchtung TA, et al. Microbial reconstitution reverses maternal diet-induced social and synaptic deficits in offspring. *Cell*. 2016;165:1762–1775.
83. Bhattarai Y, Schmidt BA, Linden DR, et al. Human-derived gut microbiota modulates colonic secretion in mice by regulating 5-HT₃ receptor expression via acetate production. *Am J Physiol Gastrointest Liver Physiol*. 2017;313:G80–g87.
84. Hsiao EY, McBride SW, Hsien S, et al. Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders. *Cell*. 2013;155:1451–1463.
85. Vuong HE, Hsiao EY. Emerging roles for the gut microbiome in autism spectrum disorder. *Biol Psychiatry*. 2017;81:411–423.
86. Ogbonnaya ES, Clarke G, Shanahan F, et al. Adult hippocampal neurogenesis is regulated by the microbiome. *Biol Psychiatry*. 2015;78:e7–e9.
87. Shin A, Preidis GA, Shulman R, et al. The gut microbiome in adult and pediatric functional gastrointestinal disorders. *Clin Gastroenterol Hepatol*. 2019;17:256–274.
88. Prado C, Michels M, Avila P, et al. The protective effects of fecal microbiota transplantation in an experimental model of necrotizing enterocolitis. *J Pediatr Surg*. 2019;54:1578–1583.
89. Kabouridis PS, Lasrado R, McCallum S, et al. Microbiota controls the homeostasis of glial cells in the gut lamina propria. *Neuron*. 2015;85:289–295.
90. Foley KF, Pantano C, Ciolino A, et al. IFN-gamma and TNF-alpha decrease serotonin transporter function and expression in Caco₂ cells. *Am J Physiol Gastrointest Liver Physiol*. 2007;292:G779–G784.
91. Foley S, Garsed K, Singh G, et al. Impaired uptake of serotonin by platelets from patients with irritable bowel syndrome correlates with duodenal immune activation. *Gastroenterology*. 2011;140:e1.
92. Furusawa Y, Obata Y, Fukuda S, et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. *Nature*. 2013;504:446–450.
93. Collins J, Borojevic R, Verdu EF, et al. Intestinal microbiota influence the early postnatal development of the enteric nervous system. *Neurogastroenterol Motil*. 2014;26:98–107.
94. Hales CM, Carroll MD, Fryar CD, et al. Prevalence of obesity among adults and youth: United States, 2015–2016. NCHS Data Brief 2017:1–8.
95. Fryar CD, Kruszon-Moran D, Gu Q, et al. Mean body weight, height, waist circumference, and body mass index among adults: United States, 1999–2000 through 2015–2016. Natl Health Stat Report 2018:1–16.
96. Avila C, Holloway AC, Hahn MK, et al. An overview of links between obesity and mental health. *Curr Obes Rep*. 2015;4:303–310.
97. Meyer-Lindenberg A, Domes G, Kirsch P, et al. Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine. *Nat Rev Neurosci*. 2011;12:524–538.
98. Striepen N, Kendrick KM, Maier W, et al. Prosocial effects of oxytocin and clinical evidence for its therapeutic potential. *Front Neuroendocrinol*. 2011;32:426–450.
99. Atladottir HO, Thorsen P, Schendel DE, et al. Association of hospitalization for infection in childhood with diagnosis of autism spectrum disorders: a Danish cohort study. *Arch Pediatr Adolesc Med*. 2010;164:470–477.
100. Atladottir HO, Henriksen TB, Schendel DE, et al. Autism after infection, febrile episodes, and antibiotic use during pregnancy: an exploratory study. *Pediatrics*. 2012;130:e1447–e1454.
101. Estes ML, McAllister AK. Maternal immune activation: implications for neuropsychiatric disorders. *Science*. 2016;353:772–777.
102. Knuesel I, Chicha L, Britschgi M, et al. Maternal immune activation and abnormal brain development across CNS disorders. *Nat Rev Neurol*. 2014;10:643–660.
103. Wu WL, Adams CE, Stevens KE, et al. The interaction between maternal immune activation and alpha 7 nicotinic acetylcholine receptor in regulating behaviors in the offspring. *Brain Behav Immun*. 2015;46:192–202.
104. Odenwald MA, Turner JR. The intestinal epithelial barrier: a therapeutic target? *Nat Rev Gastroenterol Hepatol*. 2017;14:9–21.
105. Schirmer M, Smeekens SP, Vlamakis H, et al. Linking the human gut microbiome to inflammatory cytokine production capacity. *Cell*. 2016;167:1897.
106. Zhang JC, Yao W, Dong C, et al. Blockade of interleukin-6 receptor in the periphery promotes rapid and sustained antidepressant actions: a possible role of gut-microbiota-brain axis. *Transl Psychiatry*. 2017;7:e1138.

107. Weiss R, Bitton A, Ben Shimon M, et al. Annexin A2, autoimmunity, anxiety and depression. *J Autoimmun.* 2016;73:92–99.
108. Turner JR. Intestinal mucosal barrier function in health and disease. *Nat Rev Immunol.* 2009;9:799–809.
109. Coretti L, Cristiano C, Florio E, et al. Sex-related alterations of gut microbiota composition in the BTBR mouse model of autism spectrum disorder. *Sci Rep.* 2017;7:45356.
110. Yang M, Perry K, Weber MD, et al. Social peers rescue autism-relevant sociability deficits in adolescent mice. *Autism Res.* 2011;4:17–27.
111. Ruskin DN, Murphy MI, Slade SL, et al. Ketogenic diet improves behaviors in a maternal immune activation model of autism spectrum disorder. *PLoS ONE.* 2017;12:e0171643.
112. Evangelidou A, Vlachonikolis I, Mihailidou H, et al. Application of a ketogenic diet in children with autistic behavior: pilot study. *J Child Neurol.* 2003;18:113–118.
113. Herbert MR, Buckley JA. Autism and dietary therapy: case report and review of the literature. *J Child Neurol.* 2013;28:975–982.
114. Liebhafner GM, Riemann E, Baumeister FA. Ketogenic diet in Rett syndrome. *J Child Neurol.* 2003;18:74–75.
115. Castro K, Baronio D, Perry IS, et al. The effect of ketogenic diet in an animal model of autism induced by prenatal exposure to valproic acid. *Nutr Neurosci.* 2017;20:343–350.
116. Ruskin DN, Svedova J, Cote JL, et al. Ketogenic diet improves core symptoms of autism in BTBR mice. *PLoS ONE.* 2013;8:e65021.
117. Ruskin DN, Fortin JA, Bisnauth SN, et al. Ketogenic diets improve behaviors associated with autism spectrum disorder in a sex-specific manner in the EL mouse. *Physiol Behav.* 2017;168:138–145.
118. Verpeut JL, DiCicco-Bloom E, Bello NT. Ketogenic diet exposure during the juvenile period increases social behaviors and forebrain neural activation in adult Engrailed 2 null mice. *Physiol Behav.* 2016;161:90–98.
119. Klein MS, Newell C, Bomhof MR, et al. Metabolomic Modeling To Monitor Host Responsiveness to Gut Microbiota Manipulation in the BTBR(T+tf/j) Mouse. *J Proteome Res.* 2016;15:1143–1150.
120. Newell C, Bomhof MR, Reimer RA, et al. Ketogenic diet modifies the gut microbiota in a murine model of autism spectrum disorder. *Mol Autism.* 2016;7:37.
121. David LA, Maurice CF, Carmody RN, et al. Diet rapidly and reproducibly alters the human gut microbiome. *Nature.* 2014;505:559–563.
122. Duncan SH, Lohley GE, Holtrop G, et al. Human colonic microbiota associated with diet, obesity and weight loss. *Int J Obes (Lond).* 2008;32:1720–1724.
123. Oliveira G, Diogo L, Grazina M, et al. Mitochondrial dysfunction in autism spectrum disorders: a population-based study. *Dev Med Child Neurol.* 2005;47:185–189.
124. Masino SA, Kawamura M Jr, Plotkin LM, et al. The relationship between the neuromodulator adenosine and behavioral symptoms of autism. *Neurosci Lett.* 2011;500:1–5.
125. Gano LB, Patel M, Rho JM. Ketogenic diets, mitochondria, and neurological diseases. *J Lipid Res.* 2014;55:2211–2228.
126. Naviaux JC, Schuchbauer MA, Li K, et al. Reversal of autism-like behaviors and metabolism in adult mice with single-dose antipurinergic therapy. *Transl Psychiatry.* 2014;4:e400.
127. Naviaux RK, Zolkipli Z, Wang L, et al. Antipurinergic therapy corrects the autism-like features in the poly(IC) mouse model. *PLoS ONE.* 2013;8:e57380.
128. Jackson DN, Theiss AL. Gut bacteria signaling to mitochondria in intestinal inflammation and cancer. *Gut Microbes.* 2019. <https://doi.org/10.1080/19490976.2019.1592421>.
129. Hyman SL, Stewart PA, Foley J, et al. The gluten-free/casein-free diet: a double-blind challenge trial in children with autism. *J Autism Dev Disord.* 2016;46:205–220.
130. Navarro F, Pearson DA, Fatheree N, et al. Are ‘leaky gut’ and behavior associated with gluten and dairy containing diet in children with autism spectrum disorders? *Nutr Neurosci.* 2015;18:177–185.
131. Ghalichi F, Ghaemmaghami J, Malek A, et al. Effect of gluten free diet on gastrointestinal and behavioral indices for children with autism spectrum disorders: a randomized clinical trial. *World J Pediatr.* 2016;12:436–442.
132. El-Rashidy O, El-Baz F, El-Gendy Y, et al. Ketogenic diet versus gluten free casein free diet in autistic children: a case-control study. *Metab Brain Dis.* 2017;32:1935–1941.
133. Adams JB, Audhya T, Geis E, et al. Comprehensive nutritional and dietary intervention for autism spectrum disorder—a randomized, controlled 12-month trial. *Nutrients.* 2018;10:369. <https://doi.org/10.3390/nu10030369>.
134. Liang D, Longgui N, Guoqiang X. Efficacy of different probiotic protocols in irritable bowel syndrome: a network meta-analysis. *Medicine (Baltimore).* 2019;98:e16068.
135. Arnold LE, Luna RA, Williams K, et al. Probiotics for gastrointestinal symptoms and quality of life in autism: a placebo-controlled pilot trial. *J Child Adolesc Psychopharmacol.* 2019;29:659–669.
136. Sanctuary MR, Kain JN, Chen SY, et al. Pilot study of probiotic/colostrum supplementation on gut function in children with autism and gastrointestinal symptoms. *PLoS ONE.* 2019;14:e0210064.
137. Ghaleiha A, Alikhani R, Kazemi MR, et al. Minocycline as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind placebo-controlled trial. *J Child Adolesc Psychopharmacol.* 2016;26:784–791.
138. Minshawi NF, Wink LK, Shaffer R, et al. A randomized, placebo-controlled trial of D-cycloserine for the enhancement of social skills training in autism spectrum disorders. *Mol Autism.* 2016;7:2.
139. Kang DW, Adams JB, Gregory AC, et al. Microbiota transfer therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: an open-label study. *Microbiome.* 2017;5:10.
140. Kang DW, Adams JB, Coleman DM, et al. Long-term benefit of microbiota transfer therapy on autism symptoms and gut microbiota. *Sci Rep.* 2019;9:5821.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.